Y-90 Radioembolization Plus Pembrolizumab Generates Early Efficacy Signals in HCC
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.
An abstract is unavailable.
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products
Addiction researcher Francesco Versace, Ph.D., studies how the brain responds to nicotine. Here, he answers some common questions about vaping and how it impacts brain…
Drs Merkow and Connell discuss the use of HAI therapy for patients with colorectal cancer.
The novel EHA/EBMT grading of ICAHT closely reflects the extent of hematological toxicity following BCMA- and CD19-directed CAR-T therapy.Severe ICAHT was
Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.
In a Chinese study, investigators found that sequential CD7 CAR T-cell therapy and allogeneic hematopoietic stem cell transplantation (HSCT) without graft-vs-host disease (GVHD) prophylaxis was…
An abstract is unavailable.
Treatment with autologous HER2-specifc CAR T cells was considered tolerable and produced responses in a phase 1 trial of patients with advanced sarcoma.